Research
Hormonal
Intermittent hypoxia (such as from Obstructive Sleep Apnea) activates NFκB and inflammatory mediators like TNF-α without sufficiently stabilizing HIF-1α, leading to chronic inflammation and disease progression.
If you have Obstructive Sleep Apnea (OSA), the intermittent drops in oxygen do not trigger the protective HIF-1α response seen in sustained hypoxia. Instead, they trigger inflammation (NFκB/TNF-α), which accelerates aging and disease. Treating OSA (e.g., with CPAP) is crucial to reducing this inflammatory burden.
GoodSupportsHIGH confidence
In intermittent hypoxia, a free oxygen deficit is not sufficiently established to allow HIF-1α stabilization; instead, intermittent hypoxia results in the activation of NFκB, possibly through mitochondrial stress, triggering the production of inflammatory mediators, such as TNF-α.
Why this rating
The paper reviews multiple studies (refs 67-70) on OSA and intermittent hypoxia.
Source
Hypoxia and aging
Eui‐Ju Yeo · Experimental & Molecular Medicine · 2019
DOI 10.1038/s12276-019-0233-3
narrative_reviewCited 175×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Aging is associated with reduced SIRT1 activity, which leads to decreased pVHL levels and subsequent stabilization of HIF-1α, resulting in impaired mitochondrial biogenesis and functional decline.Good
- Activation of AMPK during hypoxia and aging promotes mitochondrial biogenesis via PGC-1α and inhibits chronic inflammation by suppressing NFκB, thereby extending healthspan.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →